JAK2V617F mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevance

Clinical correlates and long‐term prognostic relevance of the JAK2V617F mutation was studied in 150 patients with essential thrombocythaemia (ET) from a single institution and followed for a median of 11·4 years. During this period, thrombotic complications were documented in 62 patients (41·3%) and transformation into acute myeloid leukaemia (AML), polycythaemia vera (PV), or myelofibrosis with myeloid metaplasia (MMM) occurred in 4 (2·7%), 8 (5·3%), and 15 (10%) patients, respectively. JAK2V617F was detected in either archived bone marrow or blood cells from 73 patients (48·7%) but none were homozygous for the mutant allele. Parameters at diagnosis that were significantly associated with the presence of JAK2V617F included advanced age and higher counts of both haemoglobin and leucocytes. During follow‐up, patients with the mutation were more likely to transform into PV but the incidences of AML, MMM, or thrombotic events were similar between patients with and without the mutation. Multivariate analysis identified advanced age, higher haemoglobin level, and thrombosis history but not the presence of JAK2V617F as independent predictors of inferior survival. Therefore, although the presence of JAK2V617F in ET appears to promote a PV phenotype, it might not carry treatment‐relevant information.

[1]  E. Estey,et al.  JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. , 2005, Blood.

[2]  D. Steensma,et al.  The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates , 2005 .

[3]  H. Heimpel,et al.  The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. , 2005, Blood.

[4]  D. Gilliland,et al.  Concomitant neutrophil JAK2V617F mutation screening and PRV‐1 expression analysis in myeloproliferative disorders and secondary polycythaemia , 2005, British journal of haematology.

[5]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.

[6]  David P Steensma,et al.  The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. , 2005, Blood.

[7]  C. Harrison.  Essential thrombocythaemia: challenges and evidence‐based management , 2005, British journal of haematology.

[8]  Qingshan Li,et al.  Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.

[9]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[10]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[11]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[12]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[13]  A. Tefferi,et al.  Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia , 2005, British journal of haematology.

[14]  松山 智洋.  What's going on 造血器腫瘍 A gain-of-function mutation of JAK2 in myeloproliferative disorders. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. N Engl J Med. 2005; 352: 1779-90. PMID:15858187.--慢性骨髄増殖性疾患においてJAK2遺伝子の変異が高頻度にみられることを示した論文 , 2005 .

[15]  D. Oscier,et al.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. , 2005, Blood.

[16]  M. Cazzola,et al.  Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. , 2004, The American journal of medicine.

[17]  A. Tefferi,et al.  Platelet‐rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV‐1 assay , 2004, British journal of haematology.

[18]  M. Cazzola,et al.  Clinical significance of neutrophil CD177 mRNA expression in Ph‐negative chronic myeloproliferative disorders , 2004, British journal of haematology.

[19]  R. Mesa,et al.  Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. , 2004, Blood.

[20]  A. Dispenzieri,et al.  FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. , 2004, Haematologica.

[21]  T. Barbui,et al.  Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. , 2004, Haematologica.

[22]  A. Tefferi,et al.  Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia. , 2003, Blood.

[23]  Juergen Thiele,et al.  Clinical and Pathological Criteria for the Diagnosis of Essential Thrombocythemia, Polycythemia Vera, and Idiopathic Myelofibrosis (Agnogenic Myeloid Metaplasia) , 2002, International journal of hematology.

[24]  J. Marsden,et al.  Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia , 2002, British journal of haematology.

[25]  R. Fonseca,et al.  A long-term retrospective study of young women with essential thrombocythemia. , 2001, Mayo Clinic proceedings.

[26]  Paulo N. Correa,et al.  Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. , 2000, Blood.

[27]  A. Tefferi,et al.  Megakaryocyte c‐Mpl expression inchronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates , 2000, European journal of haematology.

[28]  A. Mire-Sluis,et al.  Platelet c‐mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value , 1999, British journal of haematology.

[29]  C. Harrison,et al.  A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. , 1999, Blood.

[30]  E. Ikkala,et al.  Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications , 1993, British journal of haematology.

[31]  G. Faguet,et al.  Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. , 1981, Blood.